Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.mersana.com
Mersana Therapeutics News Releases
Get the latest updates from Mersana Therapeutics News Releases directly as they happen.
Follow now 37 followers
Latest posts
Last updated 8 days ago
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
8 days ago
Cost-saving initiatives expected to extend company’s cash runway and support current operating...
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
21 days ago
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
about 1 month ago
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN)...
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
about 1 month ago
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ...
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
2 months ago
Announced positive initial Phase 1 clinical data and an additional Fast Track...
Mersana Therapeutics to Present at Upcoming Investor Conferences
3 months ago
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ...
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
3 months ago
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3 months ago
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN)...
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
3 months ago
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
4 months ago
Conference call to discuss positive initial Phase 1 clinical data today at...
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
4 months ago
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety...
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
6 months ago
Plan to announce initial clinical data for XMT-1660 at a company event...